This bill creates two federal grant programs to support medical residency training in rural areas. The first program provides grants to eligible organizations (like rural hospitals, health centers, and medical schools) to establish or expand residency programs where doctors train in rural settings for over half their residency time, focusing on primary care, high-need specialties, or maternal health. The second program funds technical assistance grants to help these organizations apply for and run the training programs. The bill authorizes $12.7 million annually from 2026 to 2030, with grants for the training programs lasting up to 3 years and technical assistance grants up to 4 years.
This Senate resolution (SRES 525) condemns the Iranian government's ongoing, state-sponsored persecution of the Baha'i minority, citing decades of systemic abuses including executions, job dismissals, education bans, and property confiscations. It references UN reports and Human Rights Watch findings documenting Iran's violation of international human rights treaties, such as the Universal Declaration of Human Rights and the International Covenant on Civil and Political Rights. The resolution calls on Iran to immediately release imprisoned Baha'is, end discriminatory policies restricting their education and employment, and cease hate propaganda, while urging the U.S. President and Secretary of State to impose sanctions on Iranian officials responsible for these abuses.
This bill increases the tax exclusion for capital gains when selling a primary residence. It doubles the exclusion amount from $250,000 (for single filers) to $500,000 and from $500,000 (for married couples) to $1,000,000. The bill also adds an inflation adjustment for amounts after 2025, tying future increases to the cost-of-living adjustment. It directly affects homeowners who sell their primary residence and would otherwise owe tax on profits exceeding the previous limits. The changes apply to sales after the bill's enactment date.
This bill reestablishes the National Coal Council under the Department of Energy, as specified in a charter filed with Congress on June 16, 2025. It requires the Secretary of Energy to operate the council under the governing rules of the Federal Advisory Committee Act (excluding section 1013 of that law). The council would serve as an advisory body to the Secretary on coal-related issues, though the bill itself does not change policy or directly affect specific groups. This is a procedural measure to create a formal advisory structure, not a policy change.
This bill would strengthen U.S. sanctions against entities involved in fentanyl trafficking, with specific focus on those connected to China. It requires the President to prioritize identifying Chinese individuals and entities involved in shipping fentanyl, fentanyl analogues, and related materials to Mexico or other countries for trafficking into the U.S. The bill authorizes sanctions including blocking property and prohibiting financial transactions against foreign persons who engage in activities contributing to the international proliferation of illicit synthetic narcotics. It maintains existing sanctions on major drug cartels like the Sinaloa Cartel and establishes a 6-year sunset for new sanctions, with potential for renewal if deemed vital to national security.
HR 6372, the D.C. Shield Law Repeal Act, repeals the Human Rights Sanctuary Amendment Act of 2022 (D.C. Law 24-257), which had modified District of Columbia protections for certain immigrant residents. The bill restores the previous legal framework that existed before the 2022 amendment took effect. This directly affects D.C. law and its implementation regarding immigrant rights within the District.
HR 6407, the RCORP Authorization Act, authorizes $165 million annually (2026-2030) to fund the Rural Communities Opioid Response Program. This program provides grants to states, tribes, rural health offices, and other eligible entities to expand prevention, treatment, and recovery services for opioid and substance use disorders in rural areas. Funds can support planning, evidence-based service models, and coordination with local communities but cannot be used for real property acquisition. The bill directly affects rural communities facing opioid crises and the organizations delivering care through these grants.
This bill would amend the Anti-Terrorism Act of 1987 to designate the Muslim Brotherhood as a terrorist organization and prohibit its operations within the United States. It would require the President to designate the Muslim Brotherhood as a foreign terrorist organization under immigration law and impose new visa restrictions, including immediate revocation of current visas, for individuals identified as members. The bill mandates annual reports from the Secretary of State identifying Muslim Brotherhood branches worldwide and determining which should be designated as terrorist organizations under existing laws. These provisions would directly affect Muslim Brotherhood members, branches, and affiliated organizations seeking entry to or operating within the United States.
SRES 512 is a non-binding Senate resolution designating November 30, 2025, as "Drive Safer Sunday" to promote highway safety awareness. It encourages schools, trucking companies, clergy, law enforcement, and the public to participate in educational efforts - such as campus campaigns, driver safety reminders via CB radios, and community outreach - focusing on seat belt use and safe driving habits. The resolution specifically highlights the Sunday after Thanksgiving as a high-traffic period and references the National Highway Traffic Safety Administration's data on seat belts saving over 15,000 lives annually. As a symbolic gesture, it does not create new laws or requirements but aims to foster voluntary safety practices across communities.
S 3302, the Mikaela Naylon Give Kids a Chance Act of 2025, requires drug manufacturers developing cancer treatments to conduct pediatric-focused research for certain drugs targeting pediatric cancer mechanisms. It amends FDA drug approval processes to mandate molecularly targeted pediatric cancer investigations for drugs with new active ingredients or specific approved combinations, ensuring studies address dosing, safety, and efficacy for children. The bill also extends priority review vouchers (which expedite FDA reviews) for rare pediatric disease treatments until 2030 and mandates GAO studies to evaluate how effectively these incentives spur new pediatric cancer drug development. These changes apply to new drug applications submitted three years after the law's enactment, with reports due to Congress at 6, 8, and 10 years.
This bill requires the Veterans Health Administration to expand its existing informed consent directive (currently covering long-term opioid therapy) to include written consent for five additional medication categories: antipsychotics, stimulants, antidepressants, anxiolytics, and narcotics. It directly affects Veterans receiving VA care for these specific medications, mandating that providers obtain written informed consent before prescribing them. The key mechanism is updating VA Directive 1005 to explicitly apply to these new medication types, ensuring consistent consent processes across VA treatment. This change applies only to VA healthcare settings, not to civilian medical practices.
This bill requires the Secretaries of Defense and Veterans Affairs to evaluate existing research on menopause, perimenopause, and mid-life health for women serving in the military or who are veterans. It directs them to identify gaps in knowledge about treatments for symptoms, the impact of military service (including combat exposure and toxins like PFAS), and the availability of care and training for healthcare providers. Within 180 days of enactment, the departments must submit a report and strategic plan to Congress detailing findings and outlining steps to address research gaps and improve care. The law directly affects military women, veterans, and their healthcare providers by aiming to enhance understanding and services for menopause-related health issues.
